Conquer Mesothelioma

Actos Bladder Cancer :There is a very close relationship between survival of an individual and the stage of bladder cancer at diagnosis. For superficial disease, five year survival rates are greater than 90%. Once the cancer has spread into the bladder muscle and beyond, survival is markedly reduced. Five year survival in those with T2 disease (tumor invading superficial bladder muscle) is 60-75%, T3 disease (tumor invading deep muscle) 36-58%, and for those with T4 disease (tumor invading surrounding organs) or with node positive disease, 4-35%.’ With distant (metastatic) spread, survival at five years is less than 5%.

Most individuals with bladder cancer will undergo an initial removal of their bladder tumor by biopsy or for larger tumors by resection of their tumor via a resectoscope. For complete details see Chapter 8. Once this tumor is removed, the pathologist will determine and report on the extent of tumor invasion into the wall of the bladder. If the tumor has grown into the prostate, tissue removal via the resectoscope from this location will also be reviewed and reported pathologically. This pathologic diagnosis determines the initial stage of the cancer.

When dealing with large tumors after the initial cancer resection, your urologist may do a manual exam under anesthesia. By pressing deeply on the pelvis, the urologist may be able to palpate the tumor and assess its possible spread beyond the bladder. With modern technology and the availability of the CT scan, the manual exam is now of less importance. The CT scan can often visualize a thickened or distorted bladder wall, indicating the possibility of tumor involvement or extension through the wall. More importantly, it can determine spread to adjacent organs or lymph node involvement. Distant spread into the abdomen or beyond may also be seen. Other studies, such as the Bone Scan or Chest X ray can assess the presence and extent of metastatic diseases, MRI can be used for those with limited kidney function that cannot have a CT scan. More recently, Positron Emission Tomography (PET) scan has become available. This study can sometimes locate small deposits of metastatic disease not visible on CT or MRI scan.

More information on Actos Bladder Cancer

A catheter is a plastic or rubber tube which is placed through the urethra into the bladder. It is kept in place by a fluid filled balloon, at the end of the catheter, which is inflated in the bladder. The tube allows for drainage of urine which may be mixed with blood after a TURBT. When small tumors are removed, a catheter is not usually required unless there is a concern that you may have difficulty urinating after the procedure because of an enlarged prostate, weak bladder or swelling of the urethra after instrumentation. After large tumors are resected, a catheter is often required. It serves the following purposes:

It allows one to monitor the amount of bleeding after surgery (although the urologist attempts to stop all bleeding, this is not always possible and bleeding may persist). It provides for bladder irrigation if required. If much bleeding is present after surgery, it is important to avoid the possibility of blood clots forming and blocking the flow of urine. Irrigation can be done intermittently with a syringe or continuously via a 3 way catheter, which has a port for inflow and outflow of irrigant.

It keeps the bladder decompressed, which may be important if the resection was deep and bladder integrity is in question. The bladder may have been thinned markedly in the area of resection or biopsies. Decompression provides for reduced risk of leakage through the wall of the thinned bladder.

Information from other sources on Actos Bladder Cancer

On occasion, a urologist may face an individual with a bladder tumor that cannot be reached. This is usually much more of an issue with male patients since the scope is required to pass through a much longer urethra to begin with, therefore reducing the amount of instrument available to work within the bladder. Contributing factors include: Tumor location: tumors loeated at the dome (the very top part of the bladder or those just inside the bladder neck) may be extremely difficult to remove. Body size: individuals who are markedly obese have distorted internal anatomy. Instruments may not be long enough to reach all bladder tumors.

Enlarged bladders: individuals with abnormally large bladders may have tumors beyond the reach of the resectoscope. Bladder diverticulum: some bladders have an abnormal cavity called a diverticulum. If the opening to the diverticulum is small or if the diverticulum is large, bladder tumor removal may be difficult. In addition, the walls of the diverticulum are quite thin, making tumor removal more hazardous, as perforation is more likely to occur.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer :  Ureteral-Ileal anastomotic stenosis: The ureters are carefully attached to the base of the ileal loop. Stents are placed at the time of surgery to allow the connection to heal in an open fashion. Nevertheless, the ureteral anastomosis may scar over time, leading to blockage of the ureter and its respective kidney. The kidney becomes swollen with a dilation of its drainage system (hydronephrosis). It is routine to periodically check the condition of the kidneys after ileal loop diversion to make sure the kidneys are not becoming obstructed. Obstruction, if present, will become apparent on follow up studies.

If hydronephrosis develops, a loopogram is then obtained. In a normal ileal loop, there should be free reflux of urine up the ureters. If this reflux is gone and the kidney has recently become hydronephrotic, often an anastomotic obstruction has developed. These obstructions can form because of lack of blood flow to the end of the ureter. If the individual has had prior radiation to the pelvis, the rate of blockage is increased. On occasion, obstruction may be secondary to recurrent transitional cell cancer at the end of the ureter. This complication is either handled via an endoscopic method (using a balloon to dilate the ureter or a scope passed to the site and an incision made) or by open surgical revision and correction.

After bladder removal surgery, you will first become accustomed to your stoma, and the mechanics of keeping your collection appliance in place. The stoma is composed of the end of ileal loop (urostomy) which is brought out through the skin and everted (folded back) and secured to the skin. The location of the future stoma is usually determined prior to surgery. Ideally, it will be below your “belt line,” and definitely away from any skin indentations which can occur from body fat or scars. The stoma is red in appearance, moist, and has no sensation when you touch it. It measures approximately 1-1 Vz inches across and has been described as looking like a “rosebud.” It will be the only visible manifestation of your ileal loop diversion.

More information on Actos Bladder Cancer

Getting used to a urostomy takes time. One must overcome issues with altered body image. Real izing the removal of your bladder was necessary to preserve your life, most individuals readily accept the urostomy and its care as the price for surviving and getting on with living.

The next step is to learn how to care for it and the collection appliance. Many individuals now use a collection bag which fits directly over the urostomy with the base of the bag adherent to the surrounding skin, accomplished with a hypoallergenic adhesive. Care of the urostomy can be as simple as gently washing the skin around the stoma and then applying the adhesive bag. A seal can last around four days. Once the seal is deficient, a new bag is applied. Most collection bags snap 011 and off the underling adhesive base, which makes changing a bag possible without removing the adhesive seal. Depending on your urostomy and your preferences, your enterostomy nurse will work with you to figure out which device works best for you. Some individuals benefit by having an elastic strap secured to the bag and around their waist. Separate stretch belts are also available to help keep the ostomy bag in place.

During the day time, the urine drains directly into the bag attached over the stoma. Bags can either be transparent or opaque. Depending on bow much fluid you are drinking and how physically active you are, the bag may need to be drained approximately every four hours. Emptying the bag is accomplished easily by opening the drainage port and allowing the urine to empty directly into a toilet. If you don’t want to bother getting up in the middle of the night to drain the bag, the collection bag can be drained via a tube to a larger capacity bed side bag. This bag can be disconnected in the morning from the collection pouch.

Information from other sources on Actos Bladder Cancer

Alternatives may be considered if an individual prefers not to live with the drainage bag required with an ileal loop. With a continent diversion, a pouch is formed out of bowel beneath the skin. This pouch is extended through the skin and ends with a stoma. This stoma however, does not leak urine continuously into a bag. It requires the individual to catheterize the pouch to drain it.

The other option is called a neobladder. In this technique, a pouch is again formed out of bowel, which is then connected to the individual’s urethra. There is no stoma. Catheterization may be required to drain the pouch.

In a continent diversion, the urologist creates a pouch out of small bowel, large bowel, or a combination of the two. Through various techniques, a sphincter mechanism is created which makes the pouch continent so that no urine leaks through the stoma. No collection bag therefore is required. Ideally, the pouch eventually can hold 10-15 ounces of urine. Catheterization is required approximately every 4 hours to drain the pouch. There are many surgical techniques to create a continent diversion.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer : Within treatment trials, there are four categories, or phases. You’ll want to ask the members of your medical team which phase of clinical trial they are recommending to you and find out specific details such as the number of people involved, where the testing is being done, what benefits/drawbacks are expected for you personally, and how long the trial is expected to last.

Phase I trials study how to administer a new drug or treatment and how much of the drug or treatment can be safely tolerated. The drugs or treatment in a Phase I trial have been extensively tested in a lab and in animal studies, but not in humans. If a drug is being tested, researchers may start by giving a very low dose of the drug to those participating in the trial, then increase it gradually to determine when side effects appear and what dosage is tolerable, yet effective. Phase I trials usually enroll a small number of people at a limited number of locations. In general, they are the least likely to be of direct personal benefit to a patient, as the drugs are less well known, but occasionally they can lead to significant tumor shrinkage with side effects well within the tolerable range.

Phase II trials take the studies a step further. From the Phase I results, researchers know what dosage to give with a good margin of safely – now they are ready to test whether the drug really works as well as anticipated. They carefully monitor patients in the study for side effects and observe closely how the drug affects the cancer. A Phase II study usually targets a particular disease or type of cancer and includes fewer than 100 people.

Phase III trials involve large groups of people across a broad geographical area. A random process determines which individuals will receive the drug being tested and which ones will receive standard treatment. The idea is to compare accurately whether the new treatment is better than the old treatment and whether there are different patterns of side effects and survival. The results are monitored closely, and if one treatment is observed to be significantly more effective than the other, the trial is stopped. Sometimes a phase III trial will show that the new treatment actually is not better than the standard, in which case the new treatment is usually “dropped” from our list. The reason to “randomize” the study, choosing patients randomly for the new and standard treatments, is to avoid introducing biases into the study. For example, without randomization, there might be an inadvertent tendency to choose the younger and stronger patients for the new agent and older patients with other medical problems for the established treatment.This might make the new treatment appear to be better than the established treatment when, in fact, the differences were due only to the type of patient receiving each type of treatment.

More information on Actos Bladder Cancer

End-of-life decisions are difficult, painful, and heartbreaking. They raise issues we don’t want to face, either for ourselves or with someone we love. Yet at times, despite aggressive and thorough care, there are no further drugs or therapies or surgeries or clinical trials with curative possibilities, and the only option one’s medical team has is to recommend hospice care.

The goal of hospice care is not to cure disease; its goal is to provide palliative care – comfort, pain relief, and support – for those facing end-of-life choices. Hospice care addresses quality of life. It involves a team approach similar to the medical team model. Hospice providers offer palliative care specific to those facing an end-of-life diagnosis and their families.

Hospice care doesn’t mean that one won’t take any more medications or that there may not be some continuing therapies to help with symptoms and quality of life. In the case of advanced bladder cancer, it means that one’s medical team has determined that further medical strategies are not likely to cure one’s bladder cancer and are not likely to prolong life. Death is the likely outcome, and the emphasis of treatment will change to focus on control of symptoms. Death. It’s such a hard word. Such a scary concept. The questions pile up in one’s mind. Will there be a lot of pain or indignity? What about being physically able to enjoy the rest of life? How to take care of the overwhelming, ongoing business of life?

Information from other sources on Actos Bladder Cancer

A new or persistent pain, whether a nagging backache or a shooting pain, can signal that one’s cancer has changed or grown in some way. Doctors depend on patients to describe any pain, however intermittent or insignificant, so that they can better treat not only the disease, but any affiliated pain as well. For example, a tender, aching pain in the upper back or shoulder may indicate that cancer has moved into the chest cavity or bones. One might feel a squeezing cramp in the abdomen or a shooting pain that feels like an electrical current. However, it is also important to remember that the presence of a new pain doesn’t necessarily mean that cancer is active at that site, as pain can be due to many other factors, such as infection or inflammation.

Each of these types of pain tells doctors something different and requires a different combination of drugs and therapies to help them minimize discomfort while they’re managing the progression of the disease. Some people resist telling their doctor about pain because they think that “pain management” involves using drugs such as morphine that leave one pain-free but occasionally in a drowsy fog, and they don’t want to spend their days “doped up.” Some people simply fear the possibility of addiction, even if they are dying.

Because of the many options available today for pain control, these problems usually don’t occur, although the first few days of pain medication (before the optimal dose is found) may be associated with some drowsiness or nausea. There may be circumstances when narcotic drugs such as morphine are the best option for pain relief. But usually doctors can put together a combination of non-narcotic anti-inflammatory or nonsteroidal anti-inflammatory drugs (such as ibuprofen) that will do the trick while leaving patients alert and able to participate in some of the things they love to do, whether sewing or baking apple pie or even golfing.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer : Chemotherapy is offered most often in the face of metastatic disease or advanced local disease that cannot be removed surgically. Chemotherapy in this setting can result in complete response (disappearance of all visible tumors) in approximately 20% of patients. For these individuals, success of therapy can be monitored with imaging studies such as CT scans. Despite initial improvement, long term survival is rare.

Neoadjuvant therapy, therapy given prior to cystectomy, has several advantages. Chemotherapy is given to the patient prior to surgery when the person is strongest. Tumors can be reduced in size potentially making surgery easier when dealing with larger cancers. Earlier treatment of micro-metastatic disease may offer improved results. Most studies have demonstrated the regimens to be well tolerated and do not increase surgical complications afterwards. The downside is the delay of surgery by approximately three months which can be critical for patients whose chemotherapy is ineffective.

In addition, one must face the toxicities of this therapy which may affect the individual’s overall state of health prior to surgery. Since the true pathologic stage is unknown, many patients with organ confined disease may receive chemotherapy unnecessarily. Many oncologists reserve neoadjuvant therapy for those with disease beyond the bladder (Stage T3 or T4). Some studies have shown a reduction in mortality, while others have not. One recent article which reviewed multiple studies using neoadjuvant cisplatin based combination therapy showed a 6.5% improved survival at 5 years.

The most common regimen consists of using four different drugs MVAC (methotrexate, vinblastine, adriamycin and cisplatin) given in a 21 or 28 day cycle. During each cycle, different chemotherapy drugs are given on different days to afford maximal cancer killing effect and minimizing side effects. Generally, two cycles are given prior to assessing effectiveness and proceeding with further chemotherapy.

More information on Actos Bladder Cancer

Historically, the most effective drug regimen and the standard of care is MVAC. This combination of drugs is more effective than any drug alone. The drug regimen consists of methotrexate, vinblastine, adriamycin, and cisplatin. This regimen is difficult to tolerate. Side effects and toxicities include nausea, diarrhea, bone marrow suppression (resulting in anemia and a drop in the white blood cells, which fight infection, a drop in platelets, which help in clotting, mouth ulcers, the possibility of kidney and heart damage, and nerve impairment resulting in numbness). Because of the decline in the immune system as a result of this regimen, serious infection leading to death occurs in approximately 3% of patients. Given the serious side effects and potential for the possibility of life threatening complications, only an experienced oncologist should supervise this therapy. By careful monitoring and the use of medications to control side effects, the therapy can be made safer and easier to tolerate.

For the elderly or those individuals not in the best of health, gemcitabine combined with cisplatin (GC) have become an effective, but less toxic combination. This therapy was not originally believed to be as effective as MVAC, but is more tolerable and does not have the higher risk of serious secondary infections developing. A recent randomized trial compared MVAC with GC. In this study of 405 patients, an overall response of approximately 50% was seen with either regimen, with substantially lower toxicity with GC. Although the study cannot predict overall differences in survival, the similar response rate with reduction in toxicity has now made GC first line therapy for an increasing number of oncologists.

Information from other sources on Actos Bladder Cancer

The answer to this question must always be an individual one. It is best answered after considering the potential gain versus the potential side effccts and risks. Initial side effects experienced by almost all individuals will include nausea and vomiting, diarrhea, mouth ulcers, extreme fatigue, loss of appetite and weight loss, hair loss, and a drop in blood counts. Many of the side effects can be lessened by taking appropriate medication. Long term side effects include low blood count, nerve and kidney damage. Side effects can be severe and potentially life threatening. Death as the result of sepsis from MVAC treatment occurs in approximately 3% of patients.

Even if side effects are not severe, chemotherapy may result in the individual rapidly becoming weak and tired, reducing markedly his quality of life. The side effects for the most part are not long lasting with a return to normalcy after chemotherapy has been completed. If you are not tolerating the chemotherapy regimen well, your oncologist can modify the dose, frequency of dosing, or alter the regimen entirely.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer :  In Europe, chemotherapy drugs like mitomycin C, doxorubicin, epirubicin, and valrubicin are commonly used as first-line intravesical therapy. These agents are not considered first line in the United States because several studies have shown improved effectiveness with BCG compared to these drugs. Furthermore, unlike BCG, which decreases the risk of cancer progression to muscle invasion, these agents have never been definitively proven to have any effect on tumor progression. They are currendy considered second-line agents for patients who cannot tolerate, have a contradiction to, or fail BCG therapy. The exception to this is the use of mitomycin C as a single instillation immediately after TURBT, which has been shown to decrease the risk of bladder tumor recurrence in up to 40 percent of cases.

Intravesical therapy is performed on an outpatient basis and is generally well tolerated. Common side effects during therapy include irritative voiding symptoms like painful urination, frequency, and urgency during treatment. Each intravesical agenthas its own side effects, anditis important that you discuss this with your physician before treatment.

Systemic chemotherapy is an important part of the treatment plan for many patients with muscle-invasive and locally advanced bladder cancer. The first-line chemotherapeutic agent used for the treatment of bladder cancer is Platinol (cisplatin). Cisplatin is used most commonly in combination with other chemotherapy drugs because it has been found that the combination of medications is more effective than any single agent alone. The two most common combinations are methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) or gemcitabine and cisplatin. MVAC is an older and more extensively studied regimen, but gemcitabine-cisplatin has shown equivalent effectiveness to MVAC with fewer side effects, making it the preferred choice of many medical oncologists today. One important prerequisite to cisplatin treatment is normal kidney function. If your kidney function is impaired, your medical oncologist will likely choose other second-line chemotherapy drugs that will be less toxic to your kidneys.

More information on Actos Bladder Cancer

Chemotherapy for bladder cancer is administered either before surgery (neoadjuvant chemotherapy) or after surgery (adjuvant chemotherapy). No study has direcdy compared the effectiveness of one approach over the other, and each approach has its advantages and disadvantages. Neoadjuvant chemotherapy offers the advantage of reducing the tumor volume before surgery, which may decrease the chance of having a positive surgical margin at the time of surgery. Because it is administered early (before surgery), it has the benefit of treating the cancer at a potentially earlier stage when the burden of metastatic disease is small.

Finally, because surgeiy requires a significant amount of healing time, patients may be more “fit” for the rigors of chemotherapy before surgeiy. Several well-designed, prospective, randomized trials have demonstrated an improved survival in bladder cancer patients who undergo neoadjuvant chemotherapy. Neoadjuvant chemotherapy does have two main disadvantages. First, because our current clinical staging systems are not 100 percent accurate, a significant percentage of patients who may not need chemotherapy will be treated and subjected to its side effects. Second, upfront administration of chemotherapy may delay cystectomy in patients who do not respond to chemotherapy.

Adjuvant chemotherapy is administered after radical cystectomy. Giving chemotherapy after surgery offers the advantages of administration only to those patients who absolutely need it, and there is no delay in surgery, which minimizes risk of disease progression. The main disadvantage of adjuvant chemotherapy is a potential delay in chemotherapy for patients who need it while they are recovering from major surgery. Adjuvant chemotherapy has been less well studied than neoadjuvant chemotherapy, but studies have demonstrated its effectiveness in patients with locally advanced and lymph node-positive bladder cancer.

Information from other sources on Actos Bladder Cancer

Radiation therapy is most commonly used in combination with other treatment methods (chemotherapy and TURBT) in bladder-sparing protocols. There is little evidence to suggest that primary radiation therapy as a single agent is effective in treating non-muscle-invasive bladder cancer. Though radiation therapy is moderately effective as a primary treatment for muscle-invasive bladder cancer, 50 percent of patients treated in this manner will eventually develop metastatic disease. Additionally, many patients treated only with radiation will ultimately require a salvage cystectomy for local recurrence. External beam radiation as a sole treatment method is not currently considered adequate treatment in the United States.

Bladder preservation requires an integrated and cooperative approach from the patient, urologist, radiation oncologist, and medical oncologist. To achieve optimal success, individuals who are unlikely to respond to this therapy should be excluded, including those with evidence of cancer extending through the bladder wall (stage T3). Individuals who do not respond during the initial chemoradiation period are encouraged to undergo cystectomy. This is an important component of this approach, because those who do not respond early to bladder preservation may still be salvaged with early conversion to cystectomy. In highly selected patients, trimodal therapy has shown similar overall survival rates compared with radical cystectomy.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer :There is a very close relationship between survival of an individual and the stage of bladder cancer at diagnosis. For superficial disease, five year survival rates are greater than 90%. Once the cancer has spread into the bladder muscle and beyond, survival is markedly reduced. Five year survival in those with T2 disease (tumor invading superficial bladder muscle) is 60-75%, T3 disease (tumor invading deep muscle) 36-58%, and for those with T4 disease (tumor invading surrounding organs) or with node positive disease, 4-35%.’ With distant (metastatic) spread, survival at five years is less than 5%.

Most individuals with bladder cancer will undergo an initial removal of their bladder tumor by biopsy or for larger tumors by resection of their tumor via a resectoscope. For complete details see Chapter 8. Once this tumor is removed, the pathologist will determine and report on the extent of tumor invasion into the wall of the bladder. If the tumor has grown into the prostate, tissue removal via the resectoscope from this location will also be reviewed and reported pathologically. This pathologic diagnosis determines the initial stage of the cancer.

When dealing with large tumors after the initial cancer resection, your urologist may do a manual exam under anesthesia. By pressing deeply on the pelvis, the urologist may be able to palpate the tumor and assess its possible spread beyond the bladder. With modern technology and the availability of the CT scan, the manual exam is now of less importance. The CT scan can often visualize a thickened or distorted bladder wall, indicating the possibility of tumor involvement or extension through the wall. More importantly, it can determine spread to adjacent organs or lymph node involvement. Distant spread into the abdomen or beyond may also be seen. Other studies, such as the Bone Scan or Chest X ray can assess the presence and extent of metastatic diseases, MRI can be used for those with limited kidney function that cannot have a CT scan. More recently, Positron Emission Tomography (PET) scan has become available. This study can sometimes locate small deposits of metastatic disease not visible on CT or MRI scan.

More information on Actos Bladder Cancer

A catheter is a plastic or rubber tube which is placed through the urethra into the bladder. It is kept in place by a fluid filled balloon, at the end of the catheter, which is inflated in the bladder. The tube allows for drainage of urine which may be mixed with blood after a TURBT. When small tumors are removed, a catheter is not usually required unless there is a concern that you may have difficulty urinating after the procedure because of an enlarged prostate, weak bladder or swelling of the urethra after instrumentation. After large tumors are resected, a catheter is often required. It serves the following purposes:

It allows one to monitor the amount of bleeding after surgery (although the urologist attempts to stop all bleeding, this is not always possible and bleeding may persist). It provides for bladder irrigation if required. If much bleeding is present after surgery, it is important to avoid the possibility of blood clots forming and blocking the flow of urine. Irrigation can be done intermittently with a syringe or continuously via a 3 way catheter, which has a port for inflow and outflow of irrigant.

It keeps the bladder decompressed, which may be important if the resection was deep and bladder integrity is in question. The bladder may have been thinned markedly in the area of resection or biopsies. Decompression provides for reduced risk of leakage through the wall of the thinned bladder.

Information from other sources on Actos Bladder Cancer

On occasion, a urologist may face an individual with a bladder tumor that cannot be reached. This is usually much more of an issue with male patients since the scope is required to pass through a much longer urethra to begin with, therefore reducing the amount of instrument available to work within the bladder. Contributing factors include: Tumor location: tumors loeated at the dome (the very top part of the bladder or those just inside the bladder neck) may be extremely difficult to remove. Body size: individuals who are markedly obese have distorted internal anatomy. Instruments may not be long enough to reach all bladder tumors.

Enlarged bladders: individuals with abnormally large bladders may have tumors beyond the reach of the resectoscope. Bladder diverticulum: some bladders have an abnormal cavity called a diverticulum. If the opening to the diverticulum is small or if the diverticulum is large, bladder tumor removal may be difficult. In addition, the walls of the diverticulum are quite thin, making tumor removal more hazardous, as perforation is more likely to occur.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer :  Ureteral-Ileal anastomotic stenosis: The ureters are carefully attached to the base of the ileal loop. Stents are placed at the time of surgery to allow the connection to heal in an open fashion. Nevertheless, the ureteral anastomosis may scar over time, leading to blockage of the ureter and its respective kidney. The kidney becomes swollen with a dilation of its drainage system (hydronephrosis). It is routine to periodically check the condition of the kidneys after ileal loop diversion to make sure the kidneys are not becoming obstructed. Obstruction, if present, will become apparent on follow up studies.

If hydronephrosis develops, a loopogram is then obtained. In a normal ileal loop, there should be free reflux of urine up the ureters. If this reflux is gone and the kidney has recently become hydronephrotic, often an anastomotic obstruction has developed. These obstructions can form because of lack of blood flow to the end of the ureter. If the individual has had prior radiation to the pelvis, the rate of blockage is increased. On occasion, obstruction may be secondary to recurrent transitional cell cancer at the end of the ureter. This complication is either handled via an endoscopic method (using a balloon to dilate the ureter or a scope passed to the site and an incision made) or by open surgical revision and correction.

After bladder removal surgery, you will first become accustomed to your stoma, and the mechanics of keeping your collection appliance in place. The stoma is composed of the end of ileal loop (urostomy) which is brought out through the skin and everted (folded back) and secured to the skin. The location of the future stoma is usually determined prior to surgery. Ideally, it will be below your “belt line,” and definitely away from any skin indentations which can occur from body fat or scars. The stoma is red in appearance, moist, and has no sensation when you touch it. It measures approximately 1-1 Vz inches across and has been described as looking like a “rosebud.” It will be the only visible manifestation of your ileal loop diversion.

More information on Actos Bladder Cancer

Getting used to a urostomy takes time. One must overcome issues with altered body image. Real izing the removal of your bladder was necessary to preserve your life, most individuals readily accept the urostomy and its care as the price for surviving and getting on with living.

The next step is to learn how to care for it and the collection appliance. Many individuals now use a collection bag which fits directly over the urostomy with the base of the bag adherent to the surrounding skin, accomplished with a hypoallergenic adhesive. Care of the urostomy can be as simple as gently washing the skin around the stoma and then applying the adhesive bag. A seal can last around four days. Once the seal is deficient, a new bag is applied. Most collection bags snap 011 and off the underling adhesive base, which makes changing a bag possible without removing the adhesive seal. Depending on your urostomy and your preferences, your enterostomy nurse will work with you to figure out which device works best for you. Some individuals benefit by having an elastic strap secured to the bag and around their waist. Separate stretch belts are also available to help keep the ostomy bag in place.

During the day time, the urine drains directly into the bag attached over the stoma. Bags can either be transparent or opaque. Depending on bow much fluid you are drinking and how physically active you are, the bag may need to be drained approximately every four hours. Emptying the bag is accomplished easily by opening the drainage port and allowing the urine to empty directly into a toilet. If you don’t want to bother getting up in the middle of the night to drain the bag, the collection bag can be drained via a tube to a larger capacity bed side bag. This bag can be disconnected in the morning from the collection pouch.

Information from other sources on Actos Bladder Cancer

Alternatives may be considered if an individual prefers not to live with the drainage bag required with an ileal loop. With a continent diversion, a pouch is formed out of bowel beneath the skin. This pouch is extended through the skin and ends with a stoma. This stoma however, does not leak urine continuously into a bag. It requires the individual to catheterize the pouch to drain it.

The other option is called a neobladder. In this technique, a pouch is again formed out of bowel, which is then connected to the individual’s urethra. There is no stoma. Catheterization may be required to drain the pouch.

In a continent diversion, the urologist creates a pouch out of small bowel, large bowel, or a combination of the two. Through various techniques, a sphincter mechanism is created which makes the pouch continent so that no urine leaks through the stoma. No collection bag therefore is required. Ideally, the pouch eventually can hold 10-15 ounces of urine. Catheterization is required approximately every 4 hours to drain the pouch. There are many surgical techniques to create a continent diversion.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer : Within treatment trials, there are four categories, or phases. You’ll want to ask the members of your medical team which phase of clinical trial they are recommending to you and find out specific details such as the number of people involved, where the testing is being done, what benefits/drawbacks are expected for you personally, and how long the trial is expected to last.

Phase I trials study how to administer a new drug or treatment and how much of the drug or treatment can be safely tolerated. The drugs or treatment in a Phase I trial have been extensively tested in a lab and in animal studies, but not in humans. If a drug is being tested, researchers may start by giving a very low dose of the drug to those participating in the trial, then increase it gradually to determine when side effects appear and what dosage is tolerable, yet effective. Phase I trials usually enroll a small number of people at a limited number of locations. In general, they are the least likely to be of direct personal benefit to a patient, as the drugs are less well known, but occasionally they can lead to significant tumor shrinkage with side effects well within the tolerable range.

Phase II trials take the studies a step further. From the Phase I results, researchers know what dosage to give with a good margin of safely – now they are ready to test whether the drug really works as well as anticipated. They carefully monitor patients in the study for side effects and observe closely how the drug affects the cancer. A Phase II study usually targets a particular disease or type of cancer and includes fewer than 100 people.

Phase III trials involve large groups of people across a broad geographical area. A random process determines which individuals will receive the drug being tested and which ones will receive standard treatment. The idea is to compare accurately whether the new treatment is better than the old treatment and whether there are different patterns of side effects and survival. The results are monitored closely, and if one treatment is observed to be significantly more effective than the other, the trial is stopped. Sometimes a phase III trial will show that the new treatment actually is not better than the standard, in which case the new treatment is usually “dropped” from our list. The reason to “randomize” the study, choosing patients randomly for the new and standard treatments, is to avoid introducing biases into the study. For example, without randomization, there might be an inadvertent tendency to choose the younger and stronger patients for the new agent and older patients with other medical problems for the established treatment.This might make the new treatment appear to be better than the established treatment when, in fact, the differences were due only to the type of patient receiving each type of treatment.

More information on Actos Bladder Cancer

End-of-life decisions are difficult, painful, and heartbreaking. They raise issues we don’t want to face, either for ourselves or with someone we love. Yet at times, despite aggressive and thorough care, there are no further drugs or therapies or surgeries or clinical trials with curative possibilities, and the only option one’s medical team has is to recommend hospice care.

The goal of hospice care is not to cure disease; its goal is to provide palliative care – comfort, pain relief, and support – for those facing end-of-life choices. Hospice care addresses quality of life. It involves a team approach similar to the medical team model. Hospice providers offer palliative care specific to those facing an end-of-life diagnosis and their families.

Hospice care doesn’t mean that one won’t take any more medications or that there may not be some continuing therapies to help with symptoms and quality of life. In the case of advanced bladder cancer, it means that one’s medical team has determined that further medical strategies are not likely to cure one’s bladder cancer and are not likely to prolong life. Death is the likely outcome, and the emphasis of treatment will change to focus on control of symptoms. Death. It’s such a hard word. Such a scary concept. The questions pile up in one’s mind. Will there be a lot of pain or indignity? What about being physically able to enjoy the rest of life? How to take care of the overwhelming, ongoing business of life?

Information from other sources on Actos Bladder Cancer

A new or persistent pain, whether a nagging backache or a shooting pain, can signal that one’s cancer has changed or grown in some way. Doctors depend on patients to describe any pain, however intermittent or insignificant, so that they can better treat not only the disease, but any affiliated pain as well. For example, a tender, aching pain in the upper back or shoulder may indicate that cancer has moved into the chest cavity or bones. One might feel a squeezing cramp in the abdomen or a shooting pain that feels like an electrical current. However, it is also important to remember that the presence of a new pain doesn’t necessarily mean that cancer is active at that site, as pain can be due to many other factors, such as infection or inflammation.

Each of these types of pain tells doctors something different and requires a different combination of drugs and therapies to help them minimize discomfort while they’re managing the progression of the disease. Some people resist telling their doctor about pain because they think that “pain management” involves using drugs such as morphine that leave one pain-free but occasionally in a drowsy fog, and they don’t want to spend their days “doped up.” Some people simply fear the possibility of addiction, even if they are dying.

Because of the many options available today for pain control, these problems usually don’t occur, although the first few days of pain medication (before the optimal dose is found) may be associated with some drowsiness or nausea. There may be circumstances when narcotic drugs such as morphine are the best option for pain relief. But usually doctors can put together a combination of non-narcotic anti-inflammatory or nonsteroidal anti-inflammatory drugs (such as ibuprofen) that will do the trick while leaving patients alert and able to participate in some of the things they love to do, whether sewing or baking apple pie or even golfing.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer : Chemotherapy is offered most often in the face of metastatic disease or advanced local disease that cannot be removed surgically. Chemotherapy in this setting can result in complete response (disappearance of all visible tumors) in approximately 20% of patients. For these individuals, success of therapy can be monitored with imaging studies such as CT scans. Despite initial improvement, long term survival is rare.

Neoadjuvant therapy, therapy given prior to cystectomy, has several advantages. Chemotherapy is given to the patient prior to surgery when the person is strongest. Tumors can be reduced in size potentially making surgery easier when dealing with larger cancers. Earlier treatment of micro-metastatic disease may offer improved results. Most studies have demonstrated the regimens to be well tolerated and do not increase surgical complications afterwards. The downside is the delay of surgery by approximately three months which can be critical for patients whose chemotherapy is ineffective.

In addition, one must face the toxicities of this therapy which may affect the individual’s overall state of health prior to surgery. Since the true pathologic stage is unknown, many patients with organ confined disease may receive chemotherapy unnecessarily. Many oncologists reserve neoadjuvant therapy for those with disease beyond the bladder (Stage T3 or T4). Some studies have shown a reduction in mortality, while others have not. One recent article which reviewed multiple studies using neoadjuvant cisplatin based combination therapy showed a 6.5% improved survival at 5 years.

The most common regimen consists of using four different drugs MVAC (methotrexate, vinblastine, adriamycin and cisplatin) given in a 21 or 28 day cycle. During each cycle, different chemotherapy drugs are given on different days to afford maximal cancer killing effect and minimizing side effects. Generally, two cycles are given prior to assessing effectiveness and proceeding with further chemotherapy.

More information on Actos Bladder Cancer

Historically, the most effective drug regimen and the standard of care is MVAC. This combination of drugs is more effective than any drug alone. The drug regimen consists of methotrexate, vinblastine, adriamycin, and cisplatin. This regimen is difficult to tolerate. Side effects and toxicities include nausea, diarrhea, bone marrow suppression (resulting in anemia and a drop in the white blood cells, which fight infection, a drop in platelets, which help in clotting, mouth ulcers, the possibility of kidney and heart damage, and nerve impairment resulting in numbness). Because of the decline in the immune system as a result of this regimen, serious infection leading to death occurs in approximately 3% of patients. Given the serious side effects and potential for the possibility of life threatening complications, only an experienced oncologist should supervise this therapy. By careful monitoring and the use of medications to control side effects, the therapy can be made safer and easier to tolerate.

For the elderly or those individuals not in the best of health, gemcitabine combined with cisplatin (GC) have become an effective, but less toxic combination. This therapy was not originally believed to be as effective as MVAC, but is more tolerable and does not have the higher risk of serious secondary infections developing. A recent randomized trial compared MVAC with GC. In this study of 405 patients, an overall response of approximately 50% was seen with either regimen, with substantially lower toxicity with GC. Although the study cannot predict overall differences in survival, the similar response rate with reduction in toxicity has now made GC first line therapy for an increasing number of oncologists.

Information from other sources on Actos Bladder Cancer

The answer to this question must always be an individual one. It is best answered after considering the potential gain versus the potential side effccts and risks. Initial side effects experienced by almost all individuals will include nausea and vomiting, diarrhea, mouth ulcers, extreme fatigue, loss of appetite and weight loss, hair loss, and a drop in blood counts. Many of the side effects can be lessened by taking appropriate medication. Long term side effects include low blood count, nerve and kidney damage. Side effects can be severe and potentially life threatening. Death as the result of sepsis from MVAC treatment occurs in approximately 3% of patients.

Even if side effects are not severe, chemotherapy may result in the individual rapidly becoming weak and tired, reducing markedly his quality of life. The side effects for the most part are not long lasting with a return to normalcy after chemotherapy has been completed. If you are not tolerating the chemotherapy regimen well, your oncologist can modify the dose, frequency of dosing, or alter the regimen entirely.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer :  In Europe, chemotherapy drugs like mitomycin C, doxorubicin, epirubicin, and valrubicin are commonly used as first-line intravesical therapy. These agents are not considered first line in the United States because several studies have shown improved effectiveness with BCG compared to these drugs. Furthermore, unlike BCG, which decreases the risk of cancer progression to muscle invasion, these agents have never been definitively proven to have any effect on tumor progression. They are currendy considered second-line agents for patients who cannot tolerate, have a contradiction to, or fail BCG therapy. The exception to this is the use of mitomycin C as a single instillation immediately after TURBT, which has been shown to decrease the risk of bladder tumor recurrence in up to 40 percent of cases.

Intravesical therapy is performed on an outpatient basis and is generally well tolerated. Common side effects during therapy include irritative voiding symptoms like painful urination, frequency, and urgency during treatment. Each intravesical agenthas its own side effects, anditis important that you discuss this with your physician before treatment.

Systemic chemotherapy is an important part of the treatment plan for many patients with muscle-invasive and locally advanced bladder cancer. The first-line chemotherapeutic agent used for the treatment of bladder cancer is Platinol (cisplatin). Cisplatin is used most commonly in combination with other chemotherapy drugs because it has been found that the combination of medications is more effective than any single agent alone. The two most common combinations are methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) or gemcitabine and cisplatin. MVAC is an older and more extensively studied regimen, but gemcitabine-cisplatin has shown equivalent effectiveness to MVAC with fewer side effects, making it the preferred choice of many medical oncologists today. One important prerequisite to cisplatin treatment is normal kidney function. If your kidney function is impaired, your medical oncologist will likely choose other second-line chemotherapy drugs that will be less toxic to your kidneys.

More information on Actos Bladder Cancer

Chemotherapy for bladder cancer is administered either before surgery (neoadjuvant chemotherapy) or after surgery (adjuvant chemotherapy). No study has direcdy compared the effectiveness of one approach over the other, and each approach has its advantages and disadvantages. Neoadjuvant chemotherapy offers the advantage of reducing the tumor volume before surgery, which may decrease the chance of having a positive surgical margin at the time of surgery. Because it is administered early (before surgery), it has the benefit of treating the cancer at a potentially earlier stage when the burden of metastatic disease is small.

Finally, because surgeiy requires a significant amount of healing time, patients may be more “fit” for the rigors of chemotherapy before surgeiy. Several well-designed, prospective, randomized trials have demonstrated an improved survival in bladder cancer patients who undergo neoadjuvant chemotherapy. Neoadjuvant chemotherapy does have two main disadvantages. First, because our current clinical staging systems are not 100 percent accurate, a significant percentage of patients who may not need chemotherapy will be treated and subjected to its side effects. Second, upfront administration of chemotherapy may delay cystectomy in patients who do not respond to chemotherapy.

Adjuvant chemotherapy is administered after radical cystectomy. Giving chemotherapy after surgery offers the advantages of administration only to those patients who absolutely need it, and there is no delay in surgery, which minimizes risk of disease progression. The main disadvantage of adjuvant chemotherapy is a potential delay in chemotherapy for patients who need it while they are recovering from major surgery. Adjuvant chemotherapy has been less well studied than neoadjuvant chemotherapy, but studies have demonstrated its effectiveness in patients with locally advanced and lymph node-positive bladder cancer.

Information from other sources on Actos Bladder Cancer

Radiation therapy is most commonly used in combination with other treatment methods (chemotherapy and TURBT) in bladder-sparing protocols. There is little evidence to suggest that primary radiation therapy as a single agent is effective in treating non-muscle-invasive bladder cancer. Though radiation therapy is moderately effective as a primary treatment for muscle-invasive bladder cancer, 50 percent of patients treated in this manner will eventually develop metastatic disease. Additionally, many patients treated only with radiation will ultimately require a salvage cystectomy for local recurrence. External beam radiation as a sole treatment method is not currently considered adequate treatment in the United States.

Bladder preservation requires an integrated and cooperative approach from the patient, urologist, radiation oncologist, and medical oncologist. To achieve optimal success, individuals who are unlikely to respond to this therapy should be excluded, including those with evidence of cancer extending through the bladder wall (stage T3). Individuals who do not respond during the initial chemoradiation period are encouraged to undergo cystectomy. This is an important component of this approach, because those who do not respond early to bladder preservation may still be salvaged with early conversion to cystectomy. In highly selected patients, trimodal therapy has shown similar overall survival rates compared with radical cystectomy.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer